In 2024, the global Friedreich’s Ataxia Therapeutics market was valued at approximately USD 680 million. Driven by innovative therapeutic developments, increased patient diagnosis, and supportive healthcare initiatives, the market is projected to reach USD 1.32 billion by 2032, growing at a CAGR of 8.3% during the forecast period.